Identification and Characterization of 4-Methylbenzyl 4-[(Pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an Orally Bioavailable, Brain Penetrant NR2B Selective<i>N</i>-Methyl-<scp>d</scp>-Aspartate Receptor Antagonist
Nigel J. Liverton(United States Military Academy), Kenneth S. Koblan(Sumitomo Dainippon Pharma (United States)), Stanley L. Gaul(United States Military Academy), John A. McCauley(Fox Chase Cancer Center), Christopher F. Claiborne(Roche (Switzerland)), David A. Claremon, Anthony G. DiLella(United States Military Academy), Bohumil Bednár̂(Institute of Chemical Technology), John W. Butcher(United States Military Academy), Rodney A. Bednar(United States Military Academy), Joseph J. Lynch(United States Military Academy), Brian E. Libby(United States Military Academy), Gary L. Stump(United States Military Academy), Hao Wang(Tongji University), Kevin T. Nguyen(Navidea Biopharmaceuticals (United States)), Scott D. Mosser(United States Military Academy), Elizabeth A. Lyle, Michael E. Cunningham(Children's National), James A. Yergey, Hong Sun(United States Military Academy)
Cited by 45
Related Papers
Deep Learning for Precipitation Nowcasting: A Benchmark and A New Model
|arXiv (Cornell University)|2017|615
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577